DOP49 Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT II
Walter Reinisch(Medical University of Vienna), Séverine Vermeire(KU Leuven), Dino Tarabar(Military Medical Academy), Caleb Bliss(Takeda (United States)), William J. Sandborn(University of San Diego), Martina Goetsch(Pfizer (United States)), Fabio Cataldi(Pfizer (United States)), Silvio Danese(IRCCS Ospedale San Raffaele), Xavier Hébuterne(Université Côte d'Azur), Paul Hellstern(Clinical Research Atlanta), J S Kim(Seoul National University), Ken Gorelick(Pfizer (United States)), Miles Sparrow(Alfred Health), Charu Gupta(Cytel (United States)), Maria Kłopocka(Nicolaus Copernicus University), M. Gregus, Thomas Vanasek(Charles University)
Cited by 5
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Crohn's disease
|The Lancet|2012|2.1k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Serious Infections and Mortality in Association With Therapies for Crohn’s Disease: TREAT Registry
|Clinical Gastroenterology and Hepatology|2006|906